Given the phenotypic and functional differences observed between CAR-T cells from AML patients and healthy donors, we further analyze CD4+ and CD8+ CD33-CAR-T cells at the transcriptomic level. The gene discussed is CD8A; the disease is acute myeloid leukemia.